Evidence map›Paper›PMID 18305038›Full record

ArticleJournal of virology2008

Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.

Yossef Raviv, Robert Blumenthal, S Mark Tompkins, Jennifer Humberd, Robert J Hogan, Mathias Viard

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Clinical vaccine development for H5N1 influenza.Expert review of vaccines · 2013
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Yossef RavivNanobiology Program, Center of Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA. yraviv@ncifcrf.gov
Robert Blumenthal
S Mark Tompkins
Jennifer Humberd
Robert J Hogan
Mathias Viard
University of Georgia · USNational Institutes of Health · USCancer Institute (WIA) · IN

Funding

Mechanisms of Viral Fusion and InactivationZIABC008303 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BLUMENTHAL, ROBERT · 2009 to 2014
$2.5M
NCI NIH HHS N01 CO012400
6 · The paper itself

Abstract

The use of inactivated influenza virus for the development of vaccines with broad heterosubtypic protection requires selective inactivation techniques that eliminate viral infectivity while preserving structural integrity. Here we tested if a hydrophobic inactivation approach reported for retroviruses could be applied to the influenza virus. By this approach, the transmembrane domains of viral envelope proteins are selectively targeted by the hydrophobic photoactivatable compound 1,5-iodonaphthyl-azide (INA). This probe partitions into the lipid bilayer of the viral envelope and upon far UV irradiation reacts selectively with membrane-embedded domains of proteins and lipids while the protein domains that localize outside the bilayer remain unaffected. INA treatment of influenza virus blocked infection in a dose-dependent manner without disrupting the virion or affecting neuraminidase activity. Moreover, the virus maintained the full activity in inducing pH-dependent lipid mixing, but pH-dependent redistribution of viral envelope proteins into the target cell membrane was completely blocked. These results indicate that INA selectively blocks fusion of the virus with the target cell membrane at the pore formation and expansion step. Using a murine model of influenza virus infection, INA-inactivated influenza virus induced potent anti-influenza virus serum antibody and T-cell responses, similar to live virus immunization, and protected against heterosubtypic challenge. INA treatment of influenza A virus produced a virus that is noninfectious, intact, and fully maintains the functional activity associated with the ectodomains of its two major envelope proteins, neuraminidase and hemagglutinin. When used as a vaccine given intranasally (i.n.), INA-inactivated influenza virus induced immune responses similar to live virus infection.

Indexed as

Hydrophobic and Hydrophilic InteractionsVirus InactivationAnimalsAzidesInfluenza VaccinesMembrane FusionMiceOrthomyxoviridaeOrthomyxoviridae InfectionsTreatment OutcomeVaccines, InactivatedViral Envelope ProteinsAzidesInfluenza VaccinesiodonaphthylazideVaccines, InactivatedViral Envelope Proteins

Identifiers

PMID18305038
PMCPMC2293056
OpenAlexW1970078779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.